Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
This study has been terminated.
(The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial)
National Institute of Neurological Disorders and Stroke (NINDS)
First Posted: September 30, 2010
Last Update Posted: March 28, 2016
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )